USPTO Art Unit 1625 Prosecution Statistics

Art Unit Information

Art Unit: 1625
Group: 1620
Tech Center: 1600
Total Cases: 28,405
Last Active: March 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19094370SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATORMarch 2025April 2025Allow100YesNo
19040329TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHJanuary 2025May 2025Allow301YesNo
19024709USE OF REBOXETINE TO TREAT NARCOLEPSYJanuary 2025March 2025Allow200YesNo
18988636METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROMEDecember 2024May 2025Allow510NoNo
18978995PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOFDecember 2024April 2025Allow410YesNo
18958628MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCERNovember 2024February 2025Allow310NoNo
18956941COMPOSITIONS AND METHODS FOR TREATING CANCERNovember 2024June 2025Allow611NoNo
18945079TREATMENT OF MIGRAINENovember 2024June 2025Allow711YesNo
189255432,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA 3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2024June 2025Abandon810NoNo
18924415TREATMENT OF MIGRAINEOctober 2024March 2025Allow510NoNo
18919625DOSING REGIMEN FOR INJECTABLE CETIRIZINEOctober 2024February 2025Allow410NoNo
18903345PYRIDO[4,3-D]PYRIMIDINE COMPOUNDSOctober 2024December 2024Allow210YesNo
18895254METHOD FOR PREPARING 5-HYDROXYMETHYLFURFURALSeptember 2024February 2025Allow510NoNo
18889824PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MIGRAINESeptember 2024December 2024Allow301YesNo
18827512CRYSTALLINE FORMS OF A MENIN INHIBITORSeptember 2024June 2025Allow920NoNo
18824811METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROMESeptember 2024November 2024Allow210YesNo
18820232USE OF REBOXETINE TO TREAT NARCOLEPSYAugust 2024March 2025Allow610YesNo
18809731DEVICE AND METHOD FOR PRODUCING HIGH-PRESSURE OR SUPER HIGH-PRESSURE STEAM AS BYPRODUCT FROM MALEIC ANHYDRIDE PRODUCING DEVICEAugust 2024April 2025Allow811YesNo
188072531-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUNDAugust 2024November 2024Allow310NoNo
18804443PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOFAugust 2024October 2024Allow210NoNo
18802914CRYSTALLINE FORMS OF (E)-N-HYDROXY-3-(1-(PHENYLSULFONYL)INDOLIN-5-YL)ACRYLAMIDEAugust 2024September 2024Allow200NoNo
18795384METHODS FOR TREATING CANCERAugust 2024January 2025Allow510YesNo
18787536Systems and methods for the production of levulinic acid, furfural, and formic acidJuly 2024October 2024Allow200YesNo
187832312,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1July 2024February 2025Allow710NoNo
18783334CYCLOPROPANE SKELETON MONOPHOSPHINE LIGANDS, PALLADIUM COMPLEXES THEREOF, PREPARATION METHODS AND APPLICATIONJuly 2024March 2025Allow801NoNo
18778902METHOD FOR CONTINUOUSLY SYNTHESIZING 5-HYDROXYMETHYLFURFURAL BY USING MICRO-CHANNEL REACTORJuly 2024December 2024Allow510NoNo
18730722RESOLVIN ANALOGS COMPOUNDS, METHODS AND USES THEREOFJuly 2024February 2025Allow700NoNo
18776516TREATMENT OF MIGRAINEJuly 2024November 2024Allow401YesNo
18770589METHOD FOR SYNTHESIZING 1,3,2-DIOXATHIOLANE 2,2-DIOXIDE BY IN-SITU CATALYTIC OXIDATIONJuly 2024December 2024Allow510NoNo
18765167SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEJuly 2024December 2024Allow510NoNo
18764612COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASESJuly 2024May 2025Allow1010YesNo
18745768PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERSJune 2024June 2025Allow1210YesNo
18742346METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERSJune 2024April 2025Allow1010NoNo
18741969HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEONJune 2024January 2025Allow700YesNo
18739493METHODS OF PREPARING CANNABINOIDS OR DERIVATIVES THEREOFJune 2024December 2024Allow610NoNo
18680940DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORSMay 2024April 2025Allow1010NoNo
18676200AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOFMay 2024April 2025Allow1120YesNo
18670653LOW-TEMPERATURE CONTINUOUS-FLOW PREPARATION METHOD OF BEDAQUILINEMay 2024July 2024Allow200NoNo
18670680USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETESMay 2024May 2025Allow1220YesNo
18667992TREATMENT OF PAIN AND NEUROLOGICAL CONDITIONSMay 2024February 2025Abandon910YesNo
18710113FERROPTOSIS INHIBITOR AND USE THEREFORMay 2024February 2025Allow911YesNo
18663549METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A VEGF INHIBITOR FOR TREATING SOLID TUMORSMay 2024May 2025Allow1210NoNo
18663025TREATMENT OF MIGRAINEMay 2024July 2024Allow300YesNo
18654002BIMETALLIC METAL-ORGANIC FRAMEWORKS NANOSHEET BASED ON ZEOLITE IMIDAZOLE FRAMEWORK/MATERIALS OF INSTITUTE LAVOISIER TOPOLOGY AND PREPARATION METHOD AND APPLICATION THEREOFMay 2024October 2024Allow501NoNo
18644733Methods Of Treating Parkinson�s Disease and/or Lewy Body Disease or Disorder(s)April 2024May 2025Abandon1210YesNo
18642707PIPERIDINE COMPOUNDS AS PDE5 INHIBITORSApril 2024July 2024Allow200YesNo
18637793COMPOUNDS FOR THE REDUCING LIPOTOXIC DAMAGEApril 2024February 2025Allow1010NoNo
18637529CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTIONApril 2024May 2025Abandon1310NoNo
18633272TARGETED DEGRADATION OF VAV1April 2024August 2024Allow410NoNo
18699960COUPLED UREA MELAMINE PLANTApril 2024February 2025Allow1111NoNo
18628594METHODS OF TREATING NEUROLOGICAL DISORDERSApril 2024March 2025Allow1210NoNo
18617768NEUTROPHIL EXOCYTOSIS INHIBITORSMarch 2024August 2024Allow510YesNo
18615563MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODSMarch 2024March 2025Allow1210NoNo
18611561NANOMATERIALS COMPRISING TRIOLSMarch 2024December 2024Allow911NoNo
18606722SMALL MOLECULE COMPOUNDS HAVING NAPHTHYLAMINE STRUCTURE AND APPLICATION THEREOFMarch 2024September 2024Allow711NoNo
18692452APPLICATION OF PTGDS INHIBITOR IN PREPARATION OF DRUG FOR TREATING CATARACTSMarch 2024July 2024Allow400YesNo
18604727METHODS AND USES FOR TREATING ANHEDONIAMarch 2024October 2024Allow700YesNo
18603567WILD TYPE KIT INHIBITORSMarch 2024December 2024Allow921NoNo
18593308TREATMENT OF MIGRAINEMarch 2024October 2024Allow710NoNo
18591732SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTSFebruary 2024May 2025Allow1501NoNo
18586669METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITYFebruary 2024April 2025Abandon1310NoNo
18443965SELECTIVE REDUCTION OF a,B-UNSATURATED KETONE USING ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENEBRIDGED DIRUTHENIUM CATALYST BEARING TWO Ru(CO)(3- METHOXYPYRIDIN-2-OLATE)(PiPR3)2 MOIETIESFebruary 2024August 2024Allow610NoNo
184431364-THIAZOLIDINONE DERIVATIVES AS EGFR INHIBITORS FOR ANTI-TUMOR ACTIVITYFebruary 2024July 2024Allow501NoNo
18442393HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSIONFebruary 2024December 2024Allow1010NoNo
18440652METHODS OF ADMINISTERING ANTI-FIBROTIC THERAPYFebruary 2024November 2024Allow910NoNo
18440217TREATMENT OF MIGRAINEFebruary 2024December 2024Abandon1011NoNo
18439666HETEROCYCLIC COMPOUNDS AND USES THEREOFFebruary 2024April 2024Allow200NoNo
184372275-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PENTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDFebruary 2024July 2024Allow510NoNo
18436836PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDSFebruary 2024April 2024Allow320YesNo
18436995KRAS G12D Proteolysis Targeting ChimerasFebruary 2024August 2024Allow600YesNo
18435413METHODS FOR TREATING CANCERFebruary 2024March 2025Allow1421NoNo
18433099SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOFFebruary 2024March 2025Allow1310YesNo
18433237ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOFFebruary 2024July 2024Allow610NoNo
18429094PYRAZOLO[1,5-a]PYRIDO[4,3-e]PYRIMIDINE-3-CARBOXYLIC ACIDS AS CK2 INHIBITORSJanuary 2024May 2024Allow301YesNo
18427924N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-1-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024April 2024Allow300NoNo
18293947UREA AND MELAMINE PRODUCTIONJanuary 2024September 2024Allow710NoNo
18429126[3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDJanuary 2024October 2024Allow820NoNo
18424488CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETOJanuary 2024July 2024Allow610YesNo
18423824Method of Treating CancerJanuary 2024February 2025Abandon1310NoNo
18422517Methyl (R)-2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1H-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl (R)-2- (Fluoromethyl)-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Pyridine-3-Carboxylate As Cav1.2 ActivatorsJanuary 2024March 2025Allow1410NoNo
18421914METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROMEJanuary 2024July 2024Allow610NoNo
18416065MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOFJanuary 2024June 2025Abandon1701NoNo
18412805ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASEJanuary 2024January 2025Allow1210NoNo
18411323PYRAZOLO[1,5-a]PYRIDO[4,3-e]PYRIMIDINE-2-CARBOXYLIC ACIDS AS CK2 INHIBITORSJanuary 2024May 2024Allow401NoNo
18411842IRE1 SMALL MOLECULE INHIBITORSJanuary 2024April 2025Allow1520NoNo
18408940PYRIDO[4,3-E][1,2,3]TRIAZOLO[1,5-A]PYRIMIDINE AS CK2 INHIBITORSJanuary 2024April 2024Allow301NoNo
18409773SELECTIVE HYDROGENATION CATALYST OF a,B-UNSATURATED KETONE USING ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(2-MERCAPTOQUINOLATO)(PiPr3)2 MOIETIESJanuary 2024March 2024Allow200NoNo
18577854A PROCESS AND PLANT FOR THE SYNTHESIS OF UREA AND MELAMINEJanuary 2024April 2025Allow1521NoNo
18405638COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITORJanuary 2024August 2024Allow711NoNo
18405177SELECTIVE REDUCTION CATALYST OF a,B-UNSATURATED KETONE USING ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(8-MERCAPTOQUINOLATO(PiPr3)2 MOIETIESJanuary 2024March 2024Allow300NoNo
18404721IMIDAZO[1,5-a]PYRIDO[4,3-e]PYRIMIDINES AS CK2 INHIBITORSJanuary 2024April 2024Allow401NoNo
18403509METHODS OF PREPARING CANNABINOIDS OR DERIVATIVES THEREOFJanuary 2024March 2024Allow220NoNo
18397454COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERSDecember 2023December 2024Allow1110NoNo
18573904NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOFDecember 2023June 2024Allow600YesNo
18395377N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-2-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDDecember 2023March 2024Allow310NoNo
18395388TRIAZOLE DERIVATIVE AND USE THEREOFDecember 2023January 2025Allow1310NoNo
18393644PYRIMIDO[1',6':1,5]PYRAZOLO[4,3-B][1,7]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORSDecember 2023August 2024Allow810NoNo
18392203SELECTIVE LIGANDS FOR MODULATION OF GIRK CHANNELSDecember 2023March 2025Allow1410NoNo
18393515COMPOUNDS AND METHODS FOR INHIBITING FASCINDecember 2023July 2024Allow700YesNo
18391421PROCESSES FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOFDecember 2023December 2024Allow1210NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1625.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
100
Examiner Affirmed
54
(54.0%)
Examiner Reversed
46
(46.0%)
Reversal Percentile
91.0%
Higher than average

What This Means

With a 46.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
1125
Allowed After Appeal Filing
399
(35.5%)
Not Allowed After Appeal Filing
726
(64.5%)
Filing Benefit Percentile
62.9%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 35.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1625 - Prosecution Statistics Summary

Executive Summary

Art Unit 1625 is part of Group 1620 in Technology Center 1600. This art unit has examined 28,405 patent applications in our dataset, with an overall allowance rate of 74.8%. Applications typically reach final disposition in approximately 21 months.

Comparative Analysis

Art Unit 1625's allowance rate of 74.8% places it in the 40% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1625 receive an average of 1.26 office actions before reaching final disposition (in the 10% percentile). The median prosecution time is 21 months (in the 90% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.